• Publications
  • Influence
IDH1 and IDH2 mutations in gliomas.
BACKGROUND A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in aExpand
  • 2,523
  • 134
  • PDF
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonanceExpand
  • 1,565
  • 73
  • PDF
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
PURPOSE The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody toExpand
  • 1,267
  • 39
  • PDF
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if theExpand
  • 1,005
  • 28
  • PDF
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
PURPOSE Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is aExpand
  • 606
  • 23
  • PDF
Phase II trial of gefitinib in recurrent glioblastoma.
PURPOSE To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients withExpand
  • 707
  • 19
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
UNLABELLED Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinaseExpand
  • 246
  • 13
  • PDF
An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by nonspecific toxicity. Immunologic targeting ofExpand
  • 222
  • 12
  • PDF
Molecularly targeted therapy for malignant glioma
Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. UnderstandingExpand
  • 301
  • 11
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Despite advances in standard therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with glioblastoma multiforme (GBM) remains poor. Unfortunately,Expand
  • 220
  • 11
  • PDF